Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 4239-4242

  Uematsu, Kazutsugu ^a,b   Seki, Nobuhiko ^a   Seto, Takashi ^a   Isoe, Chie ^a   Tsukamoto, Hideo ^a   Mikami, Iwao ^c   You, Liang ^c   He, Biao ^c   Xu, Zhidong ^c   Jablons, David M ^c   Eguchi, Kenji ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dishevelled (Dvl); Malignant mesothelioma; Small interfering RNA (siRNA); Wnt pathway

Indexed keywords

CISPLATIN; DISHEVELLED PROTEIN; WNT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; COLONY FORMATION; DOWN REGULATION; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL GROWTH PROCESSES; CISPLATIN; COMBINED MODALITY THERAPY; DOWN-REGULATION; HUMANS; MESOTHELIOMA; PHOSPHOPROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 37549042329     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bueno R: Mesothelioma clinical presentation. Chest 116: 444S-445S, 1999.
2. Murayama T, Takahashi K, Natori Y and Kurumatani N: Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 49: 1-7, 2006.
3. Pisick E and Salgia R: Molecular biology of malignant mesothelioma: a review. Hematol Oncol Clin North Am 19: 997-1023, 2005.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003.
5. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C and Giaccone G: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005.
6. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004.
7. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F and Jablons DM: Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of β-catenin. Cancer Res 63: 4547-4551, 2003.
8. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F and Jablons DM: A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6: 7-14, 2004.
9. You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F and Jablons DM: Inhibition of Wnt-1 signaling induces apoptosis in β-catenin-deficient mesothelioma cells. Cancer Res 64: 3474-3478, 2004.
10. Uematsu K, He B, You L, Xu Z, McCormick F and Jablons DM: Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22: 7218-7221, 2003.
11. Tetsu O and McCormick F: β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
12. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK and Jablons DM: An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 67: 573-579, 2007.